Skip to content

Non-pharmacological techniques for cognitive improvement in schizophrenia

Investigation of the Effects of Neurostimulation Techniques in Schizophrenia and Their Impact on Executive Functioning

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-69g952
Enrollment
Unknown
Registered
2018-01-18
Start date
2014-09-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

This is a study composed by two trials to evaluate the effects of non-pharmacological techniques to cognitive improvement in schizophrenia: 1)Transcranial Direct Current Stimulation (tDCS): a paralle
anode placed over the left dorsolateral prefrontal cortex, and the cathode contralaterally, following the 10/20 EEG system. The stimulation is performed for 10 days, over two consecutive weeks (Monday
For the active stimulation, the following parameters were used: 2mA of tDCS applied for 20 minutes with electrodes of 25cm2 wrapped in cotton material soaked in saline solution. For the sham stimulati
Device
Behavioural
Other
E02.331.750

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Universidade Federal de São Paulo
Collaborator

Eligibility

Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Subjects between 18 to 65 years old diagnosed with schizophrenia; No history of substance abuse/dependence, in exception to tobacco and/or caffeine; No diagnosis of any neurological conditions (e.g. Parkinson’s disease); (d) No history of seizures; No unexplained loss of consciousness; Stability of pharmacological treatment for at least 6 weeks; No contraindications to tDCS, such as metal in the head or implanted brain medical devices; No pregnancy at enrollment; acceptance to participate in the study and provide the written informed consent.

Exclusion criteria

Exclusion criteria: Subjects with psychiatric diagnoses other than schizophrenia, except bu the health controls; Subjects with schizophrenia with predominant positive symptoms; Subject illiterate or unable to complete the cognitive assessment; IQ < 70; Clinically relevant suicide risk. Dropout was considered after absence in two consecutive tDCS sessions

Design outcomes

Primary

MeasureTime frame
Intended outcome: differences in MATRICS total score, comparing the baseline, after and follow-up measures.;Observed outcome: difference in working memory composite score, measured by the Brazilian version of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MATRICS). It was compared the baseline, after and follow-up measures. Observed results: no differences were observed for working memory after tDCS, through time*group analysis (p=0.720, IC: 95%)

Secondary

MeasureTime frame
Intended outcome: (1) Positive and Negative Syndrome Scale (PANSS) (2) Calgary Depression Scale (3) Global Assessment of Functioning Scale (GAF) The data measured in the 3 time-points will be analyzed using ANOVA, test with a 95% confidence interval.;Observed outcome: Performance in the other cognitive domains from MATRICS battery: (1) Speed of processing: Trail Making Test: Part A (TMTA), Brief Assessment of Cognition in Schizophrenia (BACS): Symbol Coding and Category Fluency Test: Animal naming (Fluency); (2) Attention: Continuous Performance Test—Identical Pairs (CPT-IP); (3) Verbal learning: Hopkins Verbal Learning Test—Revised (HVLT-R); (4) Visual learning: Brief Visuospatial Memory Test—Revised (BVMT-R); (5) Reasoning and problems solving: Neuropsychological Assessment Battery (NAB): Mazes; For schizophrenia patients, clinical assessment were used as secondary outcome: (1) Positive and Negative Syndrome Scale (PANSS) (2) Calgary Depression Scale (3) Global Assessment of Functioning Scale (GAF) All cognitive and clinical scores were analysed according to the following description: The scores measure in the 3 time-points were analyzed using generalized estimating equations (GEE) (using normal distribution, a robust estimator as covariance matrix and exchangeable correlation matrix structure). Post-hoc pairwise comparisons were run using Bonferroni adjustment for multiple comparisons. Confidence interval: 95% There was no differences for any cognitive outcome: (1) Speed of processing (p=0.306); (2) Attention/ vigilance (p=.0139); (3) Verbal Learning (p=0.696); (4) Visual Learning (p=0.891); (5) Reasoning and problem solving (p=0.154); Clinical outcomes: there was no differences for: Calgary (p=0.354) GAF (p=0.318) PANSS, positive subscale (p=0.687). There was improvement in the following subscales: PANSS negative subscale (p<0.001) PANSS general subscale (p<0.011) PANSS total subscale (p<0.001)

Countries

Brazil

Contacts

Public ContactJuly Gomes

Universidade Federal de São Paulo

july.flp@gmail.com+55 (11) 98571 8551

Outcome results

None listed

Source: REBEC (via WHO ICTRP)